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Abstract. In carbon-ion radiotherapy, single-beam delivery each day in alternate
directions has been commonly practiced for operational efficiency, taking advantage
of the Bragg peak and the relative biological effectiveness (RBE) for uniform dose
conformation to a tumor. The treatment plans are usually evaluated with total RBE-
weighted dose, which is however deficient in relevance to the biological effect in the
linear-quadratic model due to its quadratic-dose term, or the dose-fractionation effect.
In this study, we reformulate the extrapolated response dose (ERD), or synonymously
BED, which normalizes the dose-fractionation and cell-repopulation effects as well as
the RBE of treating radiation, based on inactivation of a single model cell system and a
typical treating radiation in carbon-ion RT. The ERD distribution virtually represents
the biological effect of the treatment regardless of radiation modality or fractionation
scheme. We applied the ERD formulation to simplistic model treatments and to a
preclinical survey for hypofractionation based on an actual prostate-cancer treatment of
carbon-ion radiotherapy. The proposed formulation was demonstrated to be practical
and to offer theoretical implications. In the prostate-cancer case, the ERD distribution
was very similar to the RBE-weighted-dose distribution of the actual treatment in 12
fractions. With hypofractionation, while the RBE-weighted-dose distribution varied
significantly, the ERD distribution was nearly invariant, implying that the carbon-
ion radiotherapy would be insensitive to fractionation. However, treatment evaluation
with simplistic biological dose is intrinsically limited and must be complemented in
practice somehow by clinical experiences and biology experiments.
PACS numbers: 87.53.-j, 87.53.Tf, 87.64.-t
Keywords : linear-quadratic model, biologically effective dose, relative biological
effectiveness, radiation treatment planning, multimodal radiotherapy
1. Introduction
The basis of radiotherapy (RT) for cancer treatment lies in radiobiology of human tissues
and cells. Douglas and Fowler (1976) first proposed a formula for cell-survival fraction
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as an exponential linear-quadratic (LQ) function of instantly delivered dose, on the
hypothesis that cell inactivation by lethal or double-sublethal damage was correlated
with biological reactions. In fractionated RT, the relative effectiveness per dose increases
with fraction dose according to the LQ model, which is referred to as the dose-
fractionation effect and is generally valid up to 10 Gy fractions (Fowler, 1989). In clinical
practice, radiation oncologists evaluate the total dose accumulated over the fractions for
the assessment of treatment. However, the total doses of different fractionation or of
uneven fractionation with dose varying from fraction to fraction cannot be compared
directly due to the dose-fractionation effect. The concept of extrapolated response dose
(ERD), which is more commonly referred to as biologically effective dose (BED), was
introduced to universally represent the treatment dose by the total dose in infinite
fractions for the same effect on cells (Barendsen, 1982). The ERD extrapolates the
dose-fractionation effect to its limit for universal assessment of RT treatments.
Besides dose fractionation, radiation quality modifies the relative effectiveness per
dose especially of ions whose linear energy transfer (LET) rises with depth and also
causes a Bragg peak in dose. The use of such ion beams for RT was pioneered in
the United States with dose prescription incorporating depth-dependent weighting of
relative biological effectiveness (RBE) to give a uniform biological effect (BE) in a
spread-out Bragg peak (SOBP) (Castro, 1993), followed by carbon-ion RT mainly in
Japan and Germany. The achieved high uniformity of the RBE-weighted dose (RWD)
to a tumor facilitates the delivery of single beams with daily different dose distributions
for operational efficiency. Such uneven dose fractionation except to tumor has been
commonly practiced in Japan often involving clinical studies toward hypofractionation
(Kamada et al., 2015). In Germany, carbon-ion beams have been occasionally used as a
boost in multimodal RT (Combs and Debus, 2013). Nevertheless, these treatments may
still be evaluated unconsciously with the total RWD distribution despite its deficiency
in additivity.
Dale and Jones (1999) extended the ERD concept to include RBE for high-LET
radiations. While their formulation has continually been reviewed and applied to
radiobiological studies (Carabe-Fernandez et al., 2007; Fowler, 2010; Holloway and
Dale, 2013), its direct use in treatment planning has not been realized in carbon-
ion RT. One reason may be their principle of formulation with physical dose and
radiosensitivities per cell type per radiation type, which are not directly relevant to
the treatments in the clinic and are demanding for carbon-ion beams of continuously
varying radiation quality.
In this study, we attempt to apply the ERD concept to practical and valid
assessment of carbon-ion RT treatment. In the following sections, we reformulate the
ERD from basic radiobiology, apply it to some simplistic model treatments and to a
typical prostate-cancer treatment and demonstrate its significance and usability.
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2. Methods and Materials
2.1. Radiobiological modeling
Survival factor In radiobiology, survival fraction is defined as a fraction of clonogenic
cells surviving a radiation exposure. In this paper, survival factor is termed to
additionally include the effect of inter-fraction cancer-cell repopulation. On the
hypothesis of constant rates for cell division and natural loss (Dale, 1989), the survival
factor at time t after the delivery of i-th fraction dose Di at time ti is formulated as
Si(t) = e
−αiDi−βiD2i 2(t−ti)/Td , (1)
where αi and βi are the LQ coefficients and Td is the effective doubling time for the
surviving cancer cells, which we assumed to equal the tumor-doubling time. The survival
factor at the end of a treatment in n fractions is formulated as
S =
n−1∏
i=1
Si(ti+1)Sn(tn) =
n∏
i=1
e−αiDi−βiD
2
i · eT ln 2/Td , (2)
where T = tn − t1 is the overall treatment time.
Biological effect The BE for an instant beam delivery of fraction i is defined as
EBi = − lnSi(ti) = αiDi + βiD
2
i , (3)
which statistically corresponds to the mean number of unrepaired lethal damages per
cell. The BE for an overall treatment is similarly defined as
EB = − lnS =
n∑
i=1
αiDi +
n∑
i=1
βiD
2
i −
T ln 2
Td
, (4)
where the last term represents the cell-repopulation effect.
RBE-weighted dose The RWD is defined as the dose of a reference radiation with LQ
coefficients αref and βref to cause the same BE,
EBi = αiDi + βiD
2
i = αrefDRWi + βrefDRW
2
i , (5)
with symmetric solution
D{i,RWi} =
α{i, ref}
β{i, ref}
(√
1
4
+
β{i, ref}
α2{i, ref}
EBi −
1
2
)
, (6)
which also define the RBE of the interest radiation and the total RWD,
ǫi =
DRWi
Di
and DRW =
n∑
i=1
DRWi =
n∑
i=1
ǫiDi. (7)
The total RWD is widely used for carbon-ion RT treatment, though deficient
against dose fractionation due to quadratic-term contribution and against cancer-cell
repopulation between fractions.
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Extrapolated response dose In accordance with Dale and Jones (1999), the ERD is
defined as a total physical dose of reference radiation in a hypothetical treatment of
infinite fractionation for the same BE as with the actual treatment. According to
Barendsen (1982) and Dale (1989), the ERD is the ratio of the BE to the α parameter
of interest, which is for the reference radiation in this case, or
DERi =
EBi
αref
= DRWi +
βref
αref
DRW
2
i , (8)
which consists of the linear and quadratic dose terms. The ERD for an overall treatment
is similarly defined as
DER =
EB
αref
= DRW +
βref
αref
n∑
i=1
DRWi
2
−
1
αref
T ln 2
Td
, (9)
which additionally includes the cell-repopulation term. This RWD-based formulation
is mathematically equivalent to the original formulation by Dale and Jones (1999) and
easier to use in clinical practice of carbon-ion RT, where the RWD is available.
Tumor-control probability The tumor-control probability (TCP) is radiobiologically
modeled as the probability of inactivating all of the N0 cancer cells originally existed in
a tumor (Munro and Gilbert, 1961) and is statistically given by
PTC = e
−N0S = exp
(
−N0e
−EB
)
, (10)
which should be high for a curative treatment. Inversely, when the number of cancer
cells is reasonably estimated, a curative TCP can be translated into treatment BE
EB = ln
N0
− lnPTC
. (11)
With a compensation for cancer-cell repopulation between fractions, the treatment BE
may be evenly divided into n fractions of instant BE
EB1 =
1
n
(
ln
N0
− lnPTC
+
T ln 2
Td
)
, (12)
from which fraction dose D1 and RWD DRW1 can be determined by (6) to prescribe
optimum beam deliveries for curative RT.
Beam delivery A treatment is normally prescribed with RWD to a tumor, which is
inversely converted with RBE to a physical dose to a reference point for beam-delivery
control or assessment. When multiple beams (b) are involved in a fraction, the RBE for
the fraction dose is calculated with the dose-mean LQ coefficients,
Di =
∑
b
Dib, αi =
∑
b
αib
Dib
Di
and
√
βi =
∑
b
√
βib
Dib
Di
(13)
for the mixed radiation in the LQ model (Zaider and Rossi, 1980). To allot the prescribed
RWD to the relevant beams as specified, the physical beam doses are generally derived
iteratively by the LQ model or deterministically by the lesion-additivity (LA) model
(Lam, 1987) as approximation.
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2.2. Application to simplistic model treatments
We investigated these representations of treatment dose in simplistic examples with four
model radiations of two modalities: photon radiation and three carbon-ion radiations
sampled in a typical SOBP with respective α = 0.3, 0.5, 1.0 and 1.5 Gy−1 and a common
β = 0.06 Gy−2 for radiosensitivity ofN0 = 10
7 hypothetical cancer cells in a hypothetical
fast-growing tumor with doubling time Td = 30 days, which roughly mimicked a realistic
situation (Inaniwa et al., 2015). In the following model treatments, a prescribed fraction
RWD taking the photon radiation for a reference was assumed to be delivered once a
day, seven days a week for simplicity. We generally note prescribed RWD values with
postfix “(RBE)” to clarify that they are RBE-weighted.
Dose fractionation For a carbon-ion RT treatment of total 40 Gy (RBE), we varied
the number of fractions to prescribe evenly.
Multimodal RT For a treatment initially with photons of 2 Gy per fraction for 10 days,
followed by carbon ions of 4 Gy (RBE) per fraction for 6 days to total 44 Gy (RBE) in
16 days, we evaluated the accumulation of treatment dose.
2.3. Application to a prostate-cancer treatment
Clinical dosimetry system At the National Institute of Radiological Sciences (NIRS)
in Japan, carbon-ion RT doses are prescribed in clinical dose, defined as
DCi = fCDRWi = fC ǫiDi, (14)
where clinical factor fC = 2.41 was introduced for historical reasons and RBE ǫi was
defined against a typical carbon-ion beam at a central SOBP depth as a reference
radiation on the inactivation of incubative human salivary gland (HSG) tumor cells as an
endpoint, resulting in the LQ coefficients of αref = 0.764 Gy
−1 and βref = 0.0615 Gy
−2
(Inaniwa et al., 2015). This is deviating from the conventional RBE defined against
photon radiation with the LQ coefficients of αx = 0.313 Gy
−1 and βx = 0.0615 Gy
−2
for the same endpoint (Furusawa et al., 2000). The RWD is a biologically equivalent
dose of the reference carbon-ion radiation and the clinical dose further involves artificial
rescaling to it. For distinction, we note clinical-dose values with postfix “(C)” so that 1
Gy (RBE) corresponds to 2.41 Gy (C).
Treatment For demonstration, we took a case of prostate-cancer patient who received
carbon-ion RT in 12 fractions of 4.3 Gy (C) over 3 weeks (Nomiya et al., 2014). In the
planning CT of the patient immobilized in a supine position, the clinical target volume
(CTV) included the prostate and the seminal vesicles. The planning target volume
(PTV) additionally included anterior and lateral margins of 10 mm and a posterior
margin of 5 mm. Lateral opposing carbon-ion beams were used alternately for the initial
8 fractions to cover the original PTV (PTV1) with more than 95% of the prescribed
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fraction dose, or cumulatively with about 2/3 of the prescribed total dose. To care
against the risk of complication, the rectum was fully excluded from the PTV to derive
a restricted PTV (PTV2), for which similar opposing beams with shrunk fields were
used alternately for the remaining 4 fractions. The daily beam delivery was conducted
with a pencil-beam scanning technique (Furukawa et al., 2010) to conform 4.3 Gy (C)
to the PTV with a single beam per fraction. The physical and clinical dose distributions
per fraction were calculated and stored in the treatment plan while the total clinical
dose distribution was primarily used for clinical plan assessment.
Plan distributions On the assumption of quadratic-coefficient invariance among
radiations (Inaniwa et al., 2015) in (5), the α/β-ratio for each fraction was obtained
from a set of RWD DRWi = DCi/fC and physical dose Di as
αi
βref
=
DRWi
Di
(
αref
βref
+DRWi −Di
)
. (15)
Using these data originated from the plan, we calculated the distributions of total
physical dose by
∑
iDi, total dose-mean α/β ratio by
∑
i(αi/βref)Di/
∑
iDi, total
clinical dose by
∑
iDCi and ERD by (9), where we ignored the cell-repopulation effect
on the assumption of slow-growing prostate cancer with T ≪ Td.
Hypofractionation Aside from the actual treatment, we attempted a survey toward
hypofractionation, where we reduced number of beams from four to two to simplify
the fractionation scheme while conserving the total dose. To simulate scanning beams
of stepped target dose, we fused the original-filed beams by 2/3 and the shrunk-field
beams by 1/3 per direction into the left and right beams and obtained their physical-
dose and α/β-ratio distributions. In addition, to simulate even fractionation with the
left and right beams delivered successively each day, we further fused them by 1/2
each and obtained the physical-dose and α/β-ratio distributions of a fraction. We
virtually varied number of fractions for each of the successive and alternate delivery
schemes. For the same ERD of 24.49 Gy to the prostate as with 12 fractions of 4.3 Gy
(C) by (9), we additionally prescribed fraction clinical doses of 6.124, 10.83 and 18.31
Gy (C) by (6) with EBi = (DERi/αref)/n for n = 8, 4 and 2 fractions, respectively.
Accordingly, we rescaled the respective fraction physical-dose distributions by the same
factors as for the prescribed clinical doses, or by 1.424, 2.519 and 4.258, based on the
fact that the reference radiation quality with an invariant RBE of 1 was in the prostate
somewhere that was implicitly taken as a dose reference point. We then obtained the
ERD distribution for each n from the fraction physical-dose and α/β-ratio distributions
using (5)–(9).
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Figure 1. Dose fractionation effect for evenly fractionated carbon-ion RT of total 40
Gy (RBE): (a) ERD (DER, ——) and TCP (PTC, - - - -) as functions of number of
fractions. (b) RBEs for low-α (· · · · · ·), mid-α (- - - -) and high-α (——) carbon-ion
radiations as functions of fraction RWD.
3. Results
3.1. Application to simplistic model treatments
Dose fractionation Figure 1(a) shows the representations of treatment dose for a
prescription of total 40 Gy (RBE). The ERD decreased with number of fractions due to
dose fractionation and cancer-cell repopulation and correlated with the TCP. Figure 1(b)
shows the RBEs of the three carbon-ion radiations in a SOBP. The variation of the RBEs
as well as their values decreased with the fraction RWD, which implies that the SOBP
must be designed differently for uniform treatment according to the prescribed fraction
RWD.
Multimodal RT Figure 2 shows the representations of daily cumulative dose for the
model multimodal RT treatment. By the change of fraction dose from 2 Gy with photons
to 4 Gy (RBE) with carbon ions after day 10, the ERD slope changed by a larger factor
of 2.62 due to the quadratic term. On day 16 in the end of the treatment, the cell-
repopulation term reduced the ERD by 1.16 Gy or 1.7% of the total ERD, while the
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Figure 2. A multimodal RT treatment in ten fractions of 2 Gy with photons and
six fractions of 4 Gy (RBE) with carbon ions over 16 days: cumulative RWD (DRW,
· · · · · ·), ERD (DER, ——) and TCP (PTC, - - - -) as functions of number of fractions
or days.
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Figure 3. Relation between fraction clinical dose (DC1) and fraction RWD (DRW1,
- - - -), instant ERD (DER1, ——) and the photon-equivalent dose (Dx1, · · · · · ·) in the
NIRS clinical dosimetry system.
TCP of 99.2% may be reasonably curative. If the same total RWD of 44 Gy (RBE)
were evenly delivered in 16 fractions of 2.75 Gy (RBE), the TCP would be reduced to
98.1% according to the formulas in section 2.1, indicating deficiency of the RWD-based
prescription against the change of dose fractionation. To obtain the same TCP of 99.2%
with even 16 fractions, the required RWD would be 2.83 Gy (RBE) per fraction or 45.3
Gy (RBE) in total.
3.2. Application to a prostate-cancer treatment
Figure 3 shows the relation between fraction clinical dose and fraction RWD, instant
ERD and the photon-equivalent dose in the NIRS clinical dosimetry system. The
approximation between ERD and RWD at small fraction sizes is due to minor
contribution of the quadratic term, or DRW1 ≪ αref/βref in (8).
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Figure 4. Planning CT image of the prostate-cancer patient in the isocenter plane
with green crosshairs for the right–left and anterior–posterior axes and overlaid color
wash (10%, 30%, 50%, 70%, 90%, 95%, 105% and 110%): (a) dose-mean α/β ratio
relative to 12.42 Gy, (b) total physical dose relative to 21.41 Gy, (c) total RWD relative
to 51.6 Gy (RBE) and (d) ERD relative to 24.49 Gy.
Figure 4 shows the dose distributions calculated for the actual prostate-cancer
treatment. The dose-mean α/β-ratio and physical-dose distributions were gentle in the
opposing beam arrangement while the α/β ratio was high in the anterior and posterior
sides of the prostate and the physical dose was high in the central prostate. The relative
difference between the clinical dose in figure 5(c) and the ERD in figure 5(d) was minor
due to small quadratic-term contribution at the level of 4.3 Gy (C) or 1.78 Gy (RBE)
as consistent with figure 3.
Figures 5(a) and 5(b) show the profiles of total physical dose and dose-mean α/β
ratio, where the two opposing beams were designed for 12 fractions of 4.3 Gy (C) and
were also reused for the hypofractionated treatment plans with rescaling to conserve
the ERD to the point with α/β = αref/βref . The RWD distribution in figure 5(c) was
severely deformed with hypofractionaton, while the ERD distribution in figure 5(d)
was nearly invariant, so that the plans of different fractionation cannot be compared
with RWD even relatively. The degradation of the SOBP with hypofractionation was
apparently caused by the forced reuse of the nonopimal beams in this analysis. In the
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Figure 5. Profiles on the patient right–left axis for the prostate-cancer treatment
plans: (a) dose-mean α/β ratio for inactivation of incubative HSG tumor cells, (b)
total physical dose for 12 fractions, (c) total RWD and (d) ERD with successive beam
delivery, and (e) total RWD and (f) ERD with alternate beam delivery. In (a) and (b)
are drawn the contributions of the left (- - - -) and right (· · · · · ·) beams and their total
(——) with the αref/βref = 12.42 Gy level (— · —). In (c)–(f) are drawn the treatment-
plan doses for 12 (——), 8 (- - - -), 4 (· · · · · ·) and 2 (— · —) fractions prescribed for
24.49 Gy in ERD.
outside of the SOBP in figures 5(e) and 5(f), the alternate beam delivery increased the
RWD and ERD themselves and the influence of hypofractionation on ERD.
4. Discussion
Biological dosimetry is a concept of radiation dose measurement by consequential
response of a reference biological system. The NIRS clinical dose and its relevant RWD
and ERD are model-based doses that offer virtual in vivo biological dosimetry with an
incubative HSG tumor cell of moderate radiosensitivity (Furusawa et al., 2000) as a
reference model cell system, whose choice is left as a major arbitrariness beyond this
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study. This simplification is distinctive among ERD formulations for high-LET radiation
since Dale and Jones (1999) and enabled application to patient dose distributions. The
ERD theoretically indicates a universal dose that is directly related to the BE on the
reference cells, which may be useful for preclinical and retrospective studies involving
various radiation modalities or dose fractionations. If the initial cancer-cell population-
density distribution ρ0(~r) = d
3N0/d~r as well as the ERD distribution is somehow known,
the TCP in (10) is modified to
PTC = exp
(
−
∫∫∫
ρ0(~r) e
−αref DER(~r) d~r
)
(16)
for dose-distribution assessment under the hypothesis that the tumor is formed by the
incubative reference cells.
In reality, the actual cancer and normal cells in a patient may be substantially
different from the reference in intrinsic radiosensitivity and in environmental conditions
including oxygen and biochemical concentrations, various cell interactions in tissues, etc.
The clinical sensitivity to the cell response may also vary among diseases and individuals.
There may also be differences in the time structure of radiation exposure between the
treatment and the biology experiment that determined the reference radiosensitivity
(Inaniwa et al., 2013). As a result, these biological doses may not directly be relevant to
the prognosis of treatment. Another major arbitrariness exists in the reference radiation,
which should be chosen to minimize the overall inaccuracy of cancer treatment. For
example, Kanematsu et al (2002) found a few percent inconsistency between the LQ and
LA models for RBE of a mixed carbon-ion radiation defined against a photon radiation,
which should have been minimized if the RBE had been defined to only relate similar-
radiation doses. The NIRS clinical dosimetry system, which is based on the RBE defined
against a typical treating radiation, is therefore advantageous for accurate prescription
of tumor doses in the modality-specific scale without potentially inaccurate translation
to conventional-RT doses. In fact, carbon-ion RT has been conducted according to
disease-specific treatment protocols with abundant clinical experiences including dose-
escalation studies (Kamada et al., 2015). The clinically determined curative doses per
disease and organ tolerance doses should thus be reflecting all the differences between
the reference biology experiment and the actual cancer treatments of carbon-ion RT in
its own dose scale.
In the prostate cancer treatment, the ERD distribution was very similar to the
clinical-dose distribution with 12 fractions of 4.3 Gy (C), which happens to be a typical
practice of carbon-ion RT (Kamada et al., 2015). In such a case, the clinical dose
distribution can be approximately interpreted as the ERD distribution with rescaling
by
DER
DC
=
1
fC
(
1 +
βref
αref
DˇC1
fC
)
, (17)
where DˇC1 is the fraction clinical dose prescribed to a tumor. The hypofractionation
attempted for prostate cancer treatment apparently degraded the dose concentration
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of the total RWD distribution, which was inconsistent with the ERD distribution and
thus may indicate general deficiency of RWD for hypofractionated treatments. The
observed invariance of ERD may have been caused by accidental cancelation between
the SOBP (high dose, high α/β) and its outside regions (low dose, low α/β) in the
relative dose-fractionation effect (1+Di βi/αi). The cancellation may generally be valid
for carbon-ion beams because their physical dose and LET are naturally correlated,
suggesting that carbon-ion RT may generally be insensitive to fractionation. In reality,
however, differentiation between cancer and normal cells in radiosensitivity is necessary
to evaluate the therapeutic gain by fractionation (Yoshida et al., 2015), or could be
learned from clinical experiences retrospectively (Fukahori et al., 2016).
The use of uneven fractionation such as with alternate single-beam delivery may
be a matter of clinical decision to balance between operational efficiency and dose
concentration to a tumor, which is not normally very sensitive if adequately evaluated
with ERD. The field-shrinking approach taken for the actual prostate-cancer treatment,
originated from the limitations with historical passive broad-beam delivery, should be
replaced by the field-modulation approach for multiple target volumes and doses with
pencil-beam scanning, which will simply improve the efficiency by reducing the number
of beams to plan and to verify for quality assurance.
5. Conclusions
The ERD, or synonymously BED, is a representation of treatment dose that normalizes
the effects of dose fractionation, inherent tumor growth and the RBE of treating
radiation. For assessment of carbon-ion RT treatment, we simplified the ERD concept
to biological dose for a single model cell system and reformulated it as a derivative of
clinical dose used in the clinic. The ERD will theoretically be useful for preclinical
and retrospective studies when variation in fractionation is involved. For a prostate-
cancer treatment of carbon-ion RT, we found that the ERD distribution was very similar
to the clinical dose distribution at a normal fraction size, that the ERD distribution
was nearly invariant against fractionation, that the clinical dose would not suffice
with hypofractionation and that uneven fractionation only slightly degraded the dose
concentration of even fractionation. However, treatment evaluation with simplistic
biological dose is intrinsically limited and must be complemented in practice somehow
by clinical experiences and biology experiments.
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